Search results (148)
« Back to NewsThe latest news, updates and announcements from the Nuffield Department of Medicine.
Reconstructing a lifetime of flu infections to understand long-term trends
8 November 2024
Using antibody data and mathematical modelling, a new study from researchers at the Pandemic Sciences Institute estimates annual patterns of influenza infection and protection over the past fifty years.
New research sheds light on deadly tuberculous meningitis
6 November 2024
Researchers at NDM’s Oxford University Clinical Research Unit (OUCRU) have identified gene activity signatures in the blood of patients with a life-threatening form of tuberculosis.
Novel antibody platform tackles viral mutations
29 October 2024
Scientists in the Nuffield Department of Medicine and the Icahn School of Medicine at Mount Sinai have developed an innovative antibody platform aimed at tackling one of the greatest challenges in treating rapidly evolving viruses like SARS-CoV-2: their ability to mutate and evade existing vaccines and therapies.
Study maps out next generation of drug targets in autoimmune diseases
24 October 2024
In a world first, researchers at the Kennedy Institute of Rheumatology and the Nuffield Department of Medicine have mapped the cellular dynamics following treatment with the most commonly used advanced therapy in autoimmune diseases. They have discovered why some patients benefit from this therapy while others do not, potentially paving the way for new therapies.
Long COVID study highlights need for diagnosis and management investment
23 October 2024
A new study from researchers in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), hosted at NDM’s Pandemic Sciences Institute, reveals the key Long COVID characteristics affecting populations worldwide, including fatigue, shortness of breath and having trouble thinking clearly.
Possible new transmission route for highly pathogenic avian influenza
17 October 2024
A new study published in Nature Communications has identified a new potential transmission route for H5 highly pathogenic avian influenza viruses (HPAI). Understanding actual “bird flu” rates in humans will help prevent further spillover and a potential new pandemic.
T-cell aerosol immunisation as path to universal influenza vaccine
16 October 2024
In a new study, published in NPJ Vaccines, researchers from the Pandemic Sciences Institute and The Pirbright Institute have generated new evidence supporting the development of a universal influenza vaccine.
Rift Valley fever vaccine to enter Phase II clinical trials in Kenya
14 October 2024
A promising human vaccine candidate against the potentially deadly Rift Valley fever, a mosquito-borne disease affecting countries across Africa, is set to begin Phase II trials in Kenya. This is the most advanced stage of testing a human Rift Valley fever vaccine has reached in an outbreak-prone area to date. A team of scientists at the Nuffield Department of Medicine and the KEMRI-Wellcome Trust Research Programme will lead the $3.7m trial, funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
Cancer vaccination mediates anti-tumour immunity
11 October 2024
The Van den Eynde group at the Ludwig Institute for Cancer Research have identified a new CD8+ T-cell epitope of the MAGE-type P1A tumour antigen presented in a widely-used tumour model, opening new perspectives for mechanistic studies looking at MAGE-type specific anti-tumour immunity.
Research finds that a DNA polymerase is a source of cancer mutations
10 October 2024
Researchers at Ludwig Institute for Cancer Research in the Nuffield Department of Medicine have found that cancer mutations are not solely caused by a random chemical reaction, but the human DNA polymerase ε makes errors which result in cytosine to thymine mutations.
New malaria study to support WHO guideline changes
4 October 2024
Researchers from the Centre for Tropical Medicine and Global Health at NDM have contributed to a new study which will help inform World Health Organization guidelines for treating children with Plasmodium vivax malaria. They found that giving children higher doses of primaquine substantially reduced recurrences of malaria.
Pseudouridine landscape across the human transcriptome mapped
1 October 2024
The Song group at Ludwig Oxford in the Nuffield Department of Medicine have published a technique for mapping the pseudouridine landscape across the human transcriptome.
Inflammation stimulates antimicrobial peptide release for epithelial defence
26 September 2024
The Boccellato group at NDM’s Ludwig Institute for Cancer Research have studied the regulation of antimicrobial peptide secretion in the mucus and its role in determining the colonisation of a pathogen association with stomach cancer.
New point-of-care testing to improve antibiotic use in Vietnam
24 September 2024
High levels of acceptability for a point-of-care testing service to improve antibiotic distribution for in Vietnamese pharmacies have been discovered by the Oxford University Clinical Research Unit (OUCRU), part of the Nuffield Department of Medicine.
Improving survival rates of children with sickle cell disease in Kenya
19 September 2024
Research on sickle cell disease conducted by KEMRI-Wellcome Trust Research Programme (KWTRP) at the Nuffield Department of Medicine shows significant progress in understanding how to improve survival rates and quality of life for those living with the condition.
Central Ho Chi Minh City identified as a hotspot for tuberculosis
18 September 2024
A recent study identified key factors contributing to the tuberculosis burden in Ho Chi Minh City, conducted by researchers from the Oxford University Clinical Research Unit in Vietnam (OUCRU), part of the Nuffield Department of Medicine, and Pham Ngoc Thach Hospital.
Antibiotic resistance could cause 39 million deaths between now and 2050
17 September 2024
Based on estimates across 204 countries and territories, new forecasts from the Global Research on Antimicrobial Resistance (GRAM) Project suggest that bacterial antimicrobial resistance (AMR) will cause 39 million deaths between 2025 and 2050 – equating to three deaths every minute.
Hydroxychloroquine provides moderate COVID-19 prevention
16 September 2024
Four years after being derailed by scientific fraud and politicised science in the first year of the pandemic, COPCOV, the world’s largest COVID-19 chemoprevention study, finally published results today that showed that hydroxychloroquine (HCQ) does have a moderate benefit in preventing COVID-19.
Improving understanding of lung microbiome in severe asthma patients
12 September 2024
Researchers in the Nuffield Department of Medicine, supported by NIHR Oxford Biomedical Research Centre (BRC), have discovered a link between potentially pathogenic bacteria and airways inflammation in people with severe asthma.
Adoptive T cell therapy shows an enhanced tumour response
9 September 2024
The Van den Eynde groups at the Ludwig Institute for Cancer Research in Brussels and Oxford have demonstrated that deletion of PHD2/3 enzymes in CD8 T cells shows an enhanced tumour response in various cancer models.